RNA polymerase II, I and III subunit HGenealiases: RPABC3 · RPB17 · RPB8
Q-omics provides the consensus-scored POLR2H profile across patient tissues and cancer cell-line models. POLR2H expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, POLR2H is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, POLR2H protein abundance shows 29,249 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, HNSC, and GBM as cancer lineages where POLR2H shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR2H — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR2H survival associations across molecular data types. POLR2H RNA expression shows survival associations in the most cancer types (30), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR2H RNA expression–survival associations across cancer types. High POLR2H expression shows unfavorable associations in LIHC, KICH, ACC, KIRC, LUAD and LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for POLR2H RNA expression.
This table summarizes POLR2H tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for POLR2H. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR2H shows higher tumor expression in HNSC, KIRC, BLCA, LUAD, COAD and LUSC. The HNSC box plot shows higher POLR2H RNA expression in tumor versus normal tissue (log2 FC = +1.657, t-test p < 0.001).
This table shows molecular features associated with POLR2H in patient tissues and cancer cell lines. In patient samples, POLR2H shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR2H RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
